相关实验视频

Updated: Jan 20, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

抗原丰富的瘤 - 树突细胞融合膜涂层金属纳米疫苗可实现双T细胞激活,用于强大的癌症免疫疗法

Lishang Xu¹, Kan Shao¹, Yanfei Liu²

¹Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan Province, P. R. China.

Advanced healthcare materials

|January 19, 2026

概括

一种新型纳米疫苗通过改善抗原呈现和免疫细胞激活来增强癌症免疫疗法. 这种双重作用的方法显示出显著的抗癌作用,并增强了组合治疗的潜力.

科学领域:

免疫学免疫学免疫学
纳米技术纳米技术
在瘤学瘤学.

背景情况:

癌症免疫疗法面临的挑战是抗原呈现和低免疫性.
需要新的策略来提高疫苗的疗效,以改善临床结果.

研究的目的:

开发一种用于增强癌症免疫治疗的新型纳米疫苗平台.
为了结合线粒体裂变抑制,瘤状细胞融合和纳米粒子技术.

主要方法:

用Mdivi-1预处理瘤细胞以创建抗原丰富的细胞膜 (CM(M)).
与树突细胞膜 (DCM) 融合的CM(M) 过度表达B7生物分子,形成DCCM(M).
用R848装载的金属纳米粒子 (TF/R848) 涂层DCCM(M) 制造TF/R848@DCCM(M) 纳米疫苗.

主要成果:

纳米疫苗 (TF/R848@DCCM(M)) 显示免疫性增加和抗原呈现的优化.
它通过直接和交叉呈现途径促进了双T细胞激活.
在黑色素瘤模型中观察到显著的抗癌活性,减少瘤生长和改善生存率.

结论:

开发的纳米疫苗是癌症免疫治疗的一个有前途的平台.
它增强了免疫反应,并显示了与免疫检查点抑制剂结合治疗的潜力.
这种方法为下一代瘤疫苗提供了一种多功能战略.

关键词:

细胞膜融合是细胞膜的融合.免疫激活系统的激活瘤抗原是一种瘤抗原.瘤免疫原性瘤免疫原性瘤纳米疫苗的使用

更多相关视频

B Cell Activation on an Antigen-Coated Coverslip

B Cell Activation on an Antigen-Coated Coverslip

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

The most commonly used method for generating large numbers of autologous dendritic cells (DCs) for use in tumor immunotherapy is described. The method uses IL-4 and GM-CSF to differentiate DCs from monocytes. The immature DCs are stimulated to mature and then loaded with antigens before they are injected back into the...

B Cell Activation on an Antigen-Coated Coverslip

B Cell Activation on an Antigen-Coated Coverslip

This video demonstrates B cell activation in vitro. The process involves antigen interaction with B cell receptors, leading to cytoskeleton remodeling, immune synapse formation, lysosome movement, antigen internalization, processing, and subsequent presentation on MHC molecules for B cell...

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

We describe an approach to reliably generate chimeric antigen receptor (CAR) T cells and test their differentiation and function in vitro and in...

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Evaluated in syngeneic immunocompetent hosts, cancer stem cell (CSC) based dendritic cell (DC) vaccine demonstrated significantly higher antitumor immunity than traditional DC vaccines pulsed with heterogeneous bulk tumor...

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Tumor-initiating cells (TICs) may represent a viable therapeutic target for the treatment of ovarian cancer, a highly recurrent and fatal disease. We present a protocol for culture conditions that enrich for this highly tumorigenic population of...

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Antigen-specific T cells are difficult to characterize or utilize in therapies due to their extremely low frequency. Herein, we provide a protocol to develop a magnetic particle which can bind to antigen-specific T cells to enrich these cells and then to expand them several hundred-fold for both characterization and therapy.